SIRT3 and breast cancer: Kenny et al. showed that patients with breast cancer with high expression of mtUPR markers (SIRT3, FOXO3a, SOD2, SOD1, LC3B, NRF1, and HSP60) have worse clinical outcomes compared to mtUPR-LOW patients [103].